← FDA DRUG APPROVALS

FDA ANDA · ANDA065150

AZITHROMYCIN

Sponsor: TEVA

APPLICATION
ANDA065150
TYPE
ANDA
ORIGINAL APPROVAL
2005-11-14
LATEST ACTION
2021-11-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

AZITHROMYCINDiscontinued
AZITHROMYCIN EQ 600MG BASE · TABLET · ORAL

Approval history

2021-11-22Labeling · Supplement 20 · standardAP
2021-11-15Labeling · Supplement 19 · standardAP
2017-10-18Labeling · Supplement 16 · standardAP
2017-10-18Labeling · Supplement 17 · standardAP
2017-10-18Labeling · Supplement 15 · standardAP
2015-03-20Labeling · Supplement 12 · standardAP
2015-03-20Labeling · Supplement 13 · standardAP
2013-02-28Labeling · Supplement 10 · standardAP
2012-12-18Labeling · Supplement 9 · standardAP
2011-07-01Labeling · Supplement 8AP
2010-12-13Labeling · Supplement 6AP
2010-07-28Labeling · Supplement 5AP
2009-11-30Labeling · Supplement 4AP
2009-02-12Labeling · Supplement 3AP
2005-11-14OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →